Glenmark Pharmaceuticals Inc., USA (Glenmark) has officially launched Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) in the United States. This FDA-approved treatment is bioequivalent and therapeutically equivalent to Xalatan® Ophthalmic Solution, 0.005%, originally developed by Upjohn US 2 LLC.
According to IQVIA™ sales data, the U.S. market for Xalatan® Ophthalmic Solution, 0.005% achieved approximately $113.5 million in annual sales as of December 2024. Glenmark’s introduction of this cost-effective generic alternative aims to expand patient access to this essential medication.
Marc Kikuchi, President & Business Head, North America, stated, “We are excited to introduce our fourth ophthalmic product, further expanding our presence in this segment. Glenmark remains dedicated to meeting market needs and ensuring accessibility to quality healthcare solutions.”
